These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21281874)
1. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. Kuna P; Kaczmarek J; Kupczyk M J Allergy Clin Immunol; 2011 Feb; 127(2):502-508.e1-6. PubMed ID: 21281874 [TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Tabar AI; Lizaso MT; García BE; Gómez B; Echechipía S; Aldunate MT; Madariaga B; Martínez A Pediatr Allergy Immunol; 2008 Feb; 19(1):67-75. PubMed ID: 17651380 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial. Pozzan M; Milani M Curr Med Res Opin; 2010 Dec; 26(12):2801-6. PubMed ID: 21050060 [TBL] [Abstract][Full Text] [Related]
4. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma. Tabar AI; Lizaso MT; García BE; Echechipía S; Olaguibel JM; Rodríguez A J Investig Allergol Clin Immunol; 2000; 10(6):327-33. PubMed ID: 11206932 [TBL] [Abstract][Full Text] [Related]
5. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951 [No Abstract] [Full Text] [Related]
6. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children. Caramia G; Franceschini F; Cimarelli ZA; Ciucchi MS; Gagliardini R; Ruffini E Allerg Immunol (Paris); 1996 Nov; 28(9):308-10. PubMed ID: 8986246 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of mold allergy: A review. Bozek A; Pyrkosz K Hum Vaccin Immunother; 2017 Oct; 13(10):2397-2401. PubMed ID: 28481693 [TBL] [Abstract][Full Text] [Related]
8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U; Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of alternaria alternata allergy: a prospective study in 6840 Italian asthmatic children. Cantani A; Ciaschi V Eur Rev Med Pharmacol Sci; 2004; 8(6):289-94. PubMed ID: 15745389 [TBL] [Abstract][Full Text] [Related]
10. Alternaria allergy: a three-year controlled study in children treated with immunotherapy. Cantani A; Businco E; Maglio A Allergol Immunopathol (Madr); 1988; 16(1):1-4. PubMed ID: 3381709 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy]. Ibáñez Sendín MD Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375 [TBL] [Abstract][Full Text] [Related]